Generic drugmaker Mylan on Tuesday reported lower-than-expected fourth-quarter profit and forecast 2019 earnings well below Wall Street estimates, as it grapples with significant problems at its Morgantown, West Virginia, plant. Mylan said the lower forecast was due to higher projected sales, marketing and research and development costs, and its shares fell about 10 percent. Mylan… Read More »
The other shoe has finally dropped on Mylan’s troubled manufacturing plant in West Virginia. The drugmaker acknowledged Tuesday that the FDA this month issued a warning letter for the problems at the massive site. Mylan in a statement said the November 9 warning letter was tied to the problems the FDA had already laid… Read More »
More than a month after Mylan and Pfizer reported to Health Canada that there are new issues affecting some EpiPens, the companies and the FDA notified U.S. healthcare providers of the problem which can delay treatment when the pens are needed. Mylan, Pfizer and the FDA Friday reported that some pens and their authorized generic… Read More »